» Articles » PMID: 37260767

Genetic Characterization of a Novel Organoid from Human Malignant Giant-cell Tumor

Abstract

Malignant giant-cell tumors are extremely rare bone sarcomas that transform from conventional giant-cell tumors during long periods of treatment. Owing to their rarity, no further analysis of their molecular pathogenesis exists, and thus, no standard treatment has been established. Recently, organoid culture methods have been highlighted for recapturing the tumor microenvironment, and we have applied the culture methods and succeeded in establishing patient-derived organoids (PDO) of rare sarcomas. This study aimed to investigate the genomic characteristics of our established novel organoids from human malignant giant-cell tumors. At our institute, we treated a patient with malignant giant-cell tumor. The remaining sarcoma specimens after surgical resection were cultured according to the air-liquid interface organoid-culture method. Organoids were xenografted into NOD-scid IL2Rgnull mice. The developed tumors were histologically and genomically analyzed to compare their characteristics with those of the original tumors. Genetic changes over time throughout treatment were analyzed, and the genomic status of the established organoid was confirmed. Organoids from malignant giant-cell tumors could be serially maintained using air-liquid interface organoid-culture methods. The tumors developed in xenografted NOD-scid IL2Rgnull mice. After several repetitions of the process, a patient-derived organoid line from the malignant giant-cell tumor was established. Immunohistochemical analyses and next-generation sequencing revealed that the established organoids lacked the G34W mutation. The xenografted organoids of the malignant giant-cell tumor had phenotypes histologically and genetically similar to those of the original tumor. The established organoids were confirmed to be derived from human malignant giant-cell tumors. In summary, the present study demonstrated a novel organoid model of a malignant giant-cell tumor that was genetically confirmed to be a malignant transformed tumor. Our organoid model could be used to elucidate the molecular pathogenesis of a malignant giant-cell tumor and develop novel treatment modalities.

Citing Articles

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.

Giusti V, Miserocchi G, Sbanchi G, Pannella M, Hattinger C, Cesari M Biomedicines. 2024; 12(8).

PMID: 39200384 PMC: 11352184. DOI: 10.3390/biomedicines12081921.


Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma.

Sasagawa S, Kumai J, Wakamatsu T, Yui Y Cancer Innov. 2024; 3(2):e113.

PMID: 38946933 PMC: 11212284. DOI: 10.1002/cai2.113.


Patient-Derived Organoids as a Promising Tool for Multimodal Management of Sarcomas.

Xu S, Tan S, Guo L Cancers (Basel). 2023; 15(17).

PMID: 37686615 PMC: 10486520. DOI: 10.3390/cancers15174339.

References
1.
Bourguignon L, Wong G, Earle C, Krueger K, Spevak C . Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010; 285(47):36721-35. PMC: 2978601. DOI: 10.1074/jbc.M110.162305. View

2.
Kwok W, Ling M, Lee T, Lau T, Zhou C, Zhang X . Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005; 65(12):5153-62. DOI: 10.1158/0008-5472.CAN-04-3785. View

3.
Schwartz H . Giant cell tumor of bone. Compr Ther. 1993; 19(2):64-8. View

4.
Carrle D, Bielack S . Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006; 30(6):445-51. PMC: 3172747. DOI: 10.1007/s00264-006-0192-x. View

5.
Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S . Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013; 3(5):512-9. PMC: 3763966. DOI: 10.1158/2159-8290.CD-12-0426. View